Limits...
Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma.

Sfiridaki A, Miyakis S, Pappa C, Tsirakis G, Alegakis A, Kotsis V, Stathopoulos E, Alexandrakis M - J Hematol Oncol (2011)

Bottom Line: The matrix protein osteopontin has been shown to be a marker of osteoclastic activity in multiple myeloma patients, as well as a regulator of angiogenesis.Serum osteopontin levels significantly decreased after treatment.There was a positive correlation of osteopontin with the bone turnover marker N-terminal propeptide of procollagen type I (NTx) and the angiogenic markers vascular endothelial growth factor (VEGF) and bone marrow microvessel density (r: 0.35, 0.47 and 0.30 respectively, p < 0.05).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Hematology, University Hospital of Heraklion, Crete, Greece.

ABSTRACT
The matrix protein osteopontin has been shown to be a marker of osteoclastic activity in multiple myeloma patients, as well as a regulator of angiogenesis. We measured serum levels of osteopontin in 50 untreated multiple myeloma patients (in 25, also after treatment) and examined the relation to markers of osteolytic and angiogenic activity. The median (range) of serum osteopontin was 85 (5-232) in the patient group vs. 36 (2-190) ng/ml in the control group. Serum osteopontin levels were significantly higher in patients with advanced stage or grade of myeloma disease. All patients with serum osteopontin levels >100 ng/ml had advanced stage (II or III) or high grade bone disease, whereas stage I or low grade patients had serum osteopontin levels <100ng/ml. Serum osteopontin levels significantly decreased after treatment. There was a positive correlation of osteopontin with the bone turnover marker N-terminal propeptide of procollagen type I (NTx) and the angiogenic markers vascular endothelial growth factor (VEGF) and bone marrow microvessel density (r: 0.35, 0.47 and 0.30 respectively, p < 0.05). These results support osteopontin as a dual marker of bone destruction and angiogenic activity in myeloma patients. Osteopontin represents a useful biomarker for monitoring myeloma disease activity.

Show MeSH

Related in: MedlinePlus

Serum osteopontin levels (ng/ml) according to grade of bone disease (low grade = grades 0 and 1; total 23 patients, versus high grade = grades 2 and 3; total 27 patients). Columns: 25-75% of values; bold line: median; whiskers: 95% confidence intervals. (* = p < 0.01 by Kruskal Wallis test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3102033&req=5

Figure 2: Serum osteopontin levels (ng/ml) according to grade of bone disease (low grade = grades 0 and 1; total 23 patients, versus high grade = grades 2 and 3; total 27 patients). Columns: 25-75% of values; bold line: median; whiskers: 95% confidence intervals. (* = p < 0.01 by Kruskal Wallis test).

Mentions: Opn among MM patients [median (range) 85 (5-232) ng/ml] was higher than controls [36 (2-190) ng/ml] but the difference did not reach statistical significance. However, Opn was significantly higher in 35 patients with Stage II or III compared with 15 Stage I patients (p < 0.001) (Figure 1). Similarly, there was a marked difference in Opn according to disease Grade (Figure 2), with increasing levels from Grades 0 to 3 (p = 0.006).


Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma.

Sfiridaki A, Miyakis S, Pappa C, Tsirakis G, Alegakis A, Kotsis V, Stathopoulos E, Alexandrakis M - J Hematol Oncol (2011)

Serum osteopontin levels (ng/ml) according to grade of bone disease (low grade = grades 0 and 1; total 23 patients, versus high grade = grades 2 and 3; total 27 patients). Columns: 25-75% of values; bold line: median; whiskers: 95% confidence intervals. (* = p < 0.01 by Kruskal Wallis test).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3102033&req=5

Figure 2: Serum osteopontin levels (ng/ml) according to grade of bone disease (low grade = grades 0 and 1; total 23 patients, versus high grade = grades 2 and 3; total 27 patients). Columns: 25-75% of values; bold line: median; whiskers: 95% confidence intervals. (* = p < 0.01 by Kruskal Wallis test).
Mentions: Opn among MM patients [median (range) 85 (5-232) ng/ml] was higher than controls [36 (2-190) ng/ml] but the difference did not reach statistical significance. However, Opn was significantly higher in 35 patients with Stage II or III compared with 15 Stage I patients (p < 0.001) (Figure 1). Similarly, there was a marked difference in Opn according to disease Grade (Figure 2), with increasing levels from Grades 0 to 3 (p = 0.006).

Bottom Line: The matrix protein osteopontin has been shown to be a marker of osteoclastic activity in multiple myeloma patients, as well as a regulator of angiogenesis.Serum osteopontin levels significantly decreased after treatment.There was a positive correlation of osteopontin with the bone turnover marker N-terminal propeptide of procollagen type I (NTx) and the angiogenic markers vascular endothelial growth factor (VEGF) and bone marrow microvessel density (r: 0.35, 0.47 and 0.30 respectively, p < 0.05).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Hematology, University Hospital of Heraklion, Crete, Greece.

ABSTRACT
The matrix protein osteopontin has been shown to be a marker of osteoclastic activity in multiple myeloma patients, as well as a regulator of angiogenesis. We measured serum levels of osteopontin in 50 untreated multiple myeloma patients (in 25, also after treatment) and examined the relation to markers of osteolytic and angiogenic activity. The median (range) of serum osteopontin was 85 (5-232) in the patient group vs. 36 (2-190) ng/ml in the control group. Serum osteopontin levels were significantly higher in patients with advanced stage or grade of myeloma disease. All patients with serum osteopontin levels >100 ng/ml had advanced stage (II or III) or high grade bone disease, whereas stage I or low grade patients had serum osteopontin levels <100ng/ml. Serum osteopontin levels significantly decreased after treatment. There was a positive correlation of osteopontin with the bone turnover marker N-terminal propeptide of procollagen type I (NTx) and the angiogenic markers vascular endothelial growth factor (VEGF) and bone marrow microvessel density (r: 0.35, 0.47 and 0.30 respectively, p < 0.05). These results support osteopontin as a dual marker of bone destruction and angiogenic activity in myeloma patients. Osteopontin represents a useful biomarker for monitoring myeloma disease activity.

Show MeSH
Related in: MedlinePlus